No Data
No Data
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $71
Piper Sandler analyst David Amsellem maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a buy rating, and maintains the target price at $71.According to TipRanks data, the analyst has a success rate
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Needham analyst Serge Belanger maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 42.8% and a total average return of 1.8%
Capital One Financial Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $70
Capital One Financial analyst Tim Chiang maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success r
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Health care stocks were rising Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) climbed 1
Amphastar Pharmaceuticals Holds Steady Amidst New Approval and Competitive Market
Amphastar Pharmaceuticals Gains US FDA Approval for Generic Bronchospasm Drug
Amphastar Pharmaceuticals (AMPH) said Wednesday the US Food and Drug Administration has approved its Abbreviated New Drug Application for albuterol sulfate inhalation aerosol to treat bronchospasm in